Neuroprotective effect of ultra-low doses of antibodies against S100 protein in neuroblastoma culture during oxygen and glucose deprivation

Bulletin of Experimental Biology and Medicine

Volumn 144, Issue 3, 2007, Pages 288-290

  Pankova, T M ^a   Starostina, M V ^a   Shtark, M B ^a   Epstein, O I ^b  

^a INSTITUTE OF MOLECULAR BIOLOGY AND BIOPHYSICS   (Russian Federation)

^b Materia Medica Holding Research and Production Company   (Russian Federation)

Author keywords

Antibodies; Neuro protection; Neuroblastoma; Oxygen and glucose deprivation

Indexed keywords

GLUCOSE; OXYGEN; PROTEIN ANTIBODY; PROTEIN S 100 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL HYPOXIA; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; MOUSE; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVE CELL LESION; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN;

ANIMALS; ANOXIA; ANTIBODIES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; GLUCOSE; HUMANS; MICE; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; S100 PROTEINS;

EID: 37749016307     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-007-0312-7     Document Type: Article

References (15)

1. G. A. Romanova, T. A. Voronina, et al., Sib. Vestn. Psikhiatr. Narkol., 1, No. 27, 123-125 (2003).
2. O. I. Epshtein, S. A. Sergeeva, et al., in: Proproten-100. Ultralow Doses of Affinity-Purified Antibodies against S-100 Protein [in Russian], Moscow (2002), pp. 108-112.
3. O. I. Epshtein, M. B. Shtark, et al., Pharmacology of Ultralow Doses of Antibodies against Endogenous Functional Regulators [in Russian], Moscow (2005).
4. H. Axelson, E. Fredlund, M. Ovenberger, et al., Semin. Cell Dev. Biol., 16, No. 4-5, 554-563 (2005).
5. F. Hedborg, E. Ulleras, L. Grimelius, et al., FASEB J., 17, No. 6, 598-609 (2003).
6. C. W. Heizmann, G. Fritz, and B. W. Schafer, Front. Biosci., 7, dl356-dl368 (2002).
7. J. C. Hoehner and K. Prabhakaran, J. Pediatr. Surg., 38, No. 7, 1069-1074 (2003).
8. K. L. Jin, X. O. Mao, and D. A. Greenberg, Proc. Natl. Acad. Sci. USA, 97, No. 18, 10242-10247 (2000).
9. A. Jogi, I. Ora, H. Nilsson, et al., Ibid., 99, No. 10, 7021-7026 (2002).
10. A. Jogi, I. Ora, H. Nilsson, et al., Cancer Lett., 197, No. 1-2, 145-150 (2003).
11. A. Kleindienst and M. Ross Bullock, J. Neurotrauma, 23, N 8. P. 1185-1200 (2006).
12. T. Lofstedt, A. Jogi, M. Sigvardsson, et al., J. Biol. Chem., 279, No. 38, 39223-39231 (2004).
13. H. Nilsson, A. Jogi, S. Beckman, et al., Exp. Cell. Res., 303, No. 2, 447-456 (2005).
14. S. Pahlman, M. T. Stockhausen, E. Fredlund, and H. Axelson, Semin. Cancer Biol., 14, No. 5, 365-373 (2004).
15. I. F. Smith, J. P. Boyle, and P. F. Vaughan, J. Neurochem., 79, No. 4, 867-874 (2001).